Other
LumiraDx SARS-CoV-2 & Flu A/B
LumiraDx SARS-CoV-2 & Flu A/B is an intervention with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DIAGNOSTIC TEST
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(1)
Other(1)
Detailed Status
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Trials by Status
completed150%
unknown150%
Recent Activity
0 active trials
Showing 2 of 2
completed
Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites
NCT05728970
unknown
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
NCT05787444
Clinical Trials (2)
Showing 2 of 2 trials
NCT05728970
Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites
NCT05787444
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
All 2 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 2